Monograph
C03CA04 - Torasemide |
Possibly porphyrinogenic |
PSP |
Rationale
Metabolised by CYP2C9. Torasemide is a sulfonamide congener, drug group often incriminated in porphyric attacks. One reference warns against the drug on grounds of insufficient data.
Chemical description
Sulfonamide congener.
Therapeutic characteristics
Sulfonamide loop-diuretic.
Metabolism and pharmacokinetics
Extensively CYP-metabolized in the liver, CYP2C9 is probably the most important isoenzyme. No data pointing to CYP-induction.
Personal communication
None
Published experience
None
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Torasemide. A review of its pharmacological properties and therapeutic potential.
Friedel HA, Buckley MM. Drugs. 1991 Jan;41(1):81-103. |
1706990 |
| 2. | Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes.
Miners JO, Coulter S, Birkett DJ, Goldstein JA. Pharmacogenetics. 2000 Apr;10(3):267-70. |
10803683 |
| 3. | Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism.
Miners JO, Rees DL, Valente L, Veronese ME, Birkett DJ. J Pharmacol Exp Ther. 1995 Mar;272(3):1076-81. |
7891318 |
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Belgium
United Kingdom
Norway
Poland
Luxembourg
Latvia
Serbia© NAPOS 2024